Patient characteristics.

<p>Values are mean ± S.D (plus range or number) or percentage; AF: Autofluorescence; DM: diabetes mellitus; Former smoker: smoked in the past 10 years, last year excluded; BP: blood pressure; BMI: Body Mass Index.</p

Sensitivity and specificity of skin AF alone, skin AF based decision tree (SAF-DM), FPG, HbA1c and FINDRISC for correct classification of diabetes/IGT versus normal, using OGTT based WHO criteria, or for DM/suspicion DM using HbA1c based IEC 2009 criteria.

<p>Sensitivity and specificity of skin AF alone, skin AF based decision tree (SAF-DM), FPG, HbA1c and FINDRISC for correct classification of diabetes/IGT versus normal, using OGTT based WHO criteria, or for DM/suspicion DM using HbA1c based IEC 2009 criteria.</p

Diagnostic performance of skin autofluorescence alone (SAF), the skin autofluorescence based decision-tree (SAF-DM), FPG, HbA1c and FINDRISC score ≥10 points, compared to WHO-GTT defined diabetes-IGT, or IEC 2009 HbA1c-defined diabetes/suspicion.

<p>The number of false positives (FP;n) and false negatives (FN;n), an sensitivity (S) and specificity (SP) are shown.</p

Clinical characteristics of the study population.

<p>Clinical characteristics of the study population.</p

Time course of SOFA score, Skin AF, circulating AGEs (CML and CEL), sRAGE, LDL dienes and CRP of ICU patients during 7 days starting at inclusion.

<p>Geometric mean with 95% confidence intervals. The symbols indicate the p-value compared to day 1: ns = non-significant; *:p<0.05; **:p<0.01; ***: p<0.001.Patients who died or were discharged before day 7 were excluded from this analysis. GEE repeated measurement analysis showed that SOFA score (p<0.001), LDL dienes (p<0.001) and CRP (p<0.001) were time related, while Skin AF (p = 0.09), CML (p = 0.55), CEL (p = 0.26) and sRAGE (p = 0.082) were not.</p

Dot density plot of Skin AF, serum AGEs, sRAGE, LDL dienes and CRP at inclusion, comparing ICU patients with healthy controls.

<p>Dot density plot of Skin AF, serum AGEs, sRAGE, LDL dienes and CRP at inclusion, comparing ICU patients with healthy controls.</p

Kaplan-Meier survival curves of Skin AF, serum AGEs, sRAGE, LDL dienes, CRP and the SOFA score.

<p>For each variable, the patients were split in two groups, namely those with values above the median and those having values below the median. The two groups were compared by using the log rank test.</p

Baseline characteristics of type 2 diabetes patients: total and subdivided in survivors and non-survivors expressed as mean±SD or <i>n</i> (%).

<p>Seven patients were lost to follow-up and did not define the baseline characteristics of the survivors/non-survivors.</p>a<p>Median and interquartile range.</p>b<p>Angiotensin-converting enzyme inhibitors and Angiotensin II receptor blockers.</p>c<p>Large majority represented by statins (99%). Reference values of the laboratory: HbA_1c 4.0–6.0%, creatinine 70–110 µmol/l, creatinine clearance (Cockcroft-formula) 80–120 ml/min, urinary albumin-to-creatinine ratio 0–2.5 for men and 0–3.5 for women, total cholesterol 3.5–5.0 mmol/l.</p

Baseline and outcome variables of ICU patients and healthy controls.

<p>Baseline and outcome variables of ICU patients and healthy controls.</p

Kaplan-Meier plot of the cumulative proportions of deaths in patients with previous cardiovascular disease against Standardised Survival Time.

<p>Cumulative proportions of deaths (all causes) against Standardised Survival Time (SST) in type 2 diabetes patients with previous cardiovascular disease (CVD) yes/no (+/−), compared to the expected deaths of the general population. Differences in mortality between the type 2 diabetes-subgroups and the general population are tested at SST = 0.25 and SST = 0.5. Mortality rate at SST 0.25 is 0.13 (95% CI 0.096–0.17) and an expected value is 0.076, p<0.001. At SST 0.50 mortality rate is 0.25 (95% CI 0.19–0.30) and the expected value is 0.18, p<0.0001.</p